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SICKNESS ABSENCES DUE TO CHRONIC HAND ECZEMA (CHE) IN PATIENTS
TREATED WITH ORAL ALITRETINOIN UNDER DAILY PRACTICE CONDITIONS:
RESULTS OF THE TOCCATA OBSERVATIONAL STUDY COMPRISING 522
WORKERS
Diepgen TL1, Kuessner D2
1Dept. of Social Medicine, Occupational and Environmental Dermatology, University Heidelberg,
Heidelberg, Germany, 2Basilea Pharmaceutica International Ltd., Basel, Switzerland
OBJECTIVES:CHE can lead to considerable sickness absences, but quantitative data
regarding CHE-related productivity changes under different treatments are scarce.
TheGermanobservational studyTOCCATA, collected effectiveness and tolerability
data of oral alitretinoin in daily practice and concomitantly documented informa-
tion regarding CHE-related productivity loss, the main subject of this analysis.
METHODS: A total of 680 adult CHE patients treated with oral alitretinoin for up to
24 weeks, according to the approved prescribing information, were included. Sick-
ness absence days due to CHE were documented at baseline (over the last 12
months prior to the study and when ongoing at inclusion) and at each monthly
follow-up visit (4 weeks retrospectively). This analysis focuses on the proportion of
patients with sick leave and days off work due to CHE and correlation of changes in
disease severity. RESULTS: 219 (42%) of all 522 patients in employment had sick
leaves in the last 12 months (mean: 35 days), 80 (15.4%) patients were on sick leave
at inclusion, and this proportion gradually decreased to 7.1% at observation end. In
line with this observation, the 80 patients had an average 17.6 consecutive days off
work (last 4 weeks at inclusion), however, only 7.6 days off during the four weeks
before end of observation. The highest reduction in CHE-related sickness absence
was observed between the visits 4 to 12 weeks, which was associated with the
clinical CHE improvements seen during this period.CONCLUSIONS:This is the first
report of beneficial changes in disease-related sickness absences in CHE patients
associated with successful oral alitretinoin treatment. At end of study, the number
of patientswith sickness absences due to CHEhaddecreased by approximately 50%
compared to baseline. This observation certainly merits further exploration in dif-
ferent health care settings potentially confirming economic benefits for patients,
their employers and the society at large.
SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes & Patient
Preference Studies
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COMPARISON OF A 24-HOUR AND 7-DAY VERSION OF A PATIENT REPORTED
OUTCOME MEASURE FOR PSORIASIS SYMPTOM SEVERITY
Bushnell DM1, Martin ML2, McCarrier KP2, Chiou CF3, Ortmeier B4
1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Health Research Associates,
Inc., Seattle, WA, USA, 3Janssen Global Services, Companies of Johnson & Johnson, Raritan, NJ,
USA, 4Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVES: Research about the limitations of cognitive processes in memory
suggest retrospective recall may be less accurate than recall within the past 24
hours. Daily diaries, however, are often more burdensome for study subjects and
are more expensive to administer than weekly retrospective instruments. We
sought to evaluate a 24-hour recall version (24-hour PSI) and a 7-day retrospective
version (7-day PSI) of the Psoriasis Symptom Inventory (PSI) to test the equivalence
of symptom severity assessed with the two versions.METHODS: Using a prospec-
tive, observational design, adult patients receiving usual care for their plaque pso-
riasis (Psoriasis Area and Severity Index [PASI]10) were recruited from clinics and
randomized. Subjects completed the 24-hour PSI for 7 days and completed the
7-day PSI on the seventh day. Comparison of average daily diary scores and 7-day
retrospective scores were made with Pearson’s correlation coefficients and simple
bivariate comparisons (t-test). Potential exposure effects of daily PSI administra-
tion in the days preceding the 7-day retrospective assessment were examined in
sensitivity analyses. RESULTS: Among the 139 subjects, mean age and PASI scores
were 51.2 and 17.6, respectively. There was high agreement between results from
the daily 24-hour PSI and the 7-day PSI assessments. With the exception of Flaking
(0.08, p0.02), no significant mean differences were found in the remaining seven
PSI symptoms (Itching, Redness, Scaling, Burning, Stinging, Cracking, and Pain) between
the 24-hour PSI (7-day average) and the 7-day PSI. Correlations between the two PSI
versions ranged from 0.86 (scaling) to 0.92 (pain). Completion of the daily assess-
ment did not influence responses on the 7-day PSI.CONCLUSIONS:Overall findings
show that the two PSI versions yield equivalent results. Both the 24-hour PSI and
7-day PSI would provide comprehensive capture of symptoms in psoriasis studies
and clinical trials.
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VALIDATION OF THE PAEDIATRIC HEARING IMPAIRMENT CAREGIVER
EXPERIENCE (PHICE) INSTRUMENT
Lim HYL1, Xiang L2, Li R1, Wong N1, Yuen CPK3
1National University Health System, Singapore, 2National University of Singapore, Singapore,
3The Hong Kong Institute of Education, Tai Po, New Territories, Hong Kong
OBJECTIVES: To validate and shorten the Paediatric Hearing Impairment Caregiver
Experience (PHICE) instrument. METHODS: A total of 125 caregivers of hearing
impaired children attending the otolaryngology, audiology, and aural rehabilita-
tion at a local clinic were administered the 68 item questionnaire. Exploratory
factor analysis was conducted. A 5 factor structure was adopted and items with
high cross-loadings were dropped. The 5 factor structure was then analysed using
confirmatory factor analysis. Cronbach’s  was computed to assess internal
consistency. RESULTS: A 5 factor structure corresponding to the factors: Adapta-
tion to hearing loss, Childcare support, Healthcare, Education and Policywas
adopted. Confirmatory factor analysis suggest a good model fit (RMSEA  0.067,
RMR 0.329, SRMR 0.0752, NFI 0.830, CFI 0.949). This model fit is assessed to
be superior than the original 8 factor structure. Cronbach’s were high (0.75) for
each subscale. 3 questions that were deemed important from a clinical point of
view butwas removedwould continue to be a part of the instrument but will not be
used in the computation of the subscale scores. CONCLUSIONS: The 68 item ques-
tionnaire has been reduced to 39 items. A new 5 factor structure is proposed that
better explains the underlying items. Three items was added back despite being
dropped due to their important clinical value.
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COMPARATIVE STUDY OF THE PERFORMANCES OF GENERIC AND DISEASE-
SPECIFIC MEASURES IN CATARACT PATIENTS
Suh JK, Doctor J
USC School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: To evaluate the overall performances of generic and disease-specific
measures.METHODS:One disease-specific and five genericmeasureswere admin-
istered in cataract patients at baseline, 1- and 6-month. The disease-specific mea-
sure was the National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)
and the genericmeasures included the Short Form-6D (SF-6D), EuroQol-5D (EQ-5D),
Self-Administered Quality of Well-being Scale (QWB-SA), and two versions of the
Health Utilities Index (HUI2 and HUI3). The global rating of change, in a 5-point
rating scale, was applied as an anchor and the score change between baseline and
6-month was calculated accordingly. Two definitions for responders who experi-
enced a minimally important difference were used: patients whose global ratings
were “somewhat better” or above (Model 1) and patients rated as “somewhat bet-
ter” or above, or “somewhat worse” or below (Model 2). In Model 2, for the patients
who reported “somewhat worse” or below, the sign of the score changes were
reversed. In Experiment 1 the performance of the generic measure was compared
against the VFQ-25 based on Model 1. In Experiment2 the impact of using different
classifications for the responderswas examined by comparing the performances of
Model 1 and Model 2 for each measure. The performances of the measures were
compared based on the areas under the receiver operating characteristics curves.
RESULTS: A total of 223 cataract patients were included. In Experiment 1, only the
EQ-5D showed significantly lower performance than the VFQ-25 (p0.0001) and
there were no differences between the VFQ-25 and the other generic measures. In
Experiment 2, the performances between Model 1 and 2 were not significant in all
the measures. CONCLUSIONS: In this cataract population, we found that the ge-
nericmeasureswere as sensitive as the disease-specificmeasure inmost cases and
the performance of themeasure did not depend on the different definitions for the
responder.
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ASSESSING PRURITUS AMONG PATIENTS WITH ATOPIC DERMATITIS:
TARGETED LITERATURE AND INSTRUMENT REVIEW
Brown T1, Olanrewaju O1, Deal L2, Katz E3, Chiou CF3, Martin S1, Fehnel S1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2eResearch Technology Inc, Philadelphia,
PA, USA, 3Janssen Global Services, LLC, West Hills, CA, USA
OBJECTIVES: Pruritus is a key criterion in the diagnosis of atopic dermatitis (AD)
and has been associated with lower levels of health-related quality of life in both
pediatric and adult patients. The objective of this studywas to identify information
and instruments relevant to the measurement of pruritus in adolescent and adult
AD patients. METHODS: A PubMed search was conducted to identify relevant lit-
erature and existing PROmeasures (items, subscales, and instruments) designed to
assess the severity, frequency, and/or impact of AD-related pruritus. Articles were
limited to studies conducted in humans, published since 2000, and in English.
Search terms included atopic dermatitis, itch, and pruritus. In addition to using
sources identified during the literature review, a search of published PRO instru-
ment sources (e.g., Patient-Reported Outcome & Quality of Life Instruments Data-
base [PROQOLID]) and the RTI-HS internal PRO instrument repository was con-
ducted. Identified PRO instruments were evaluated based on the criteria described
in the Food and Drug Administration’s 2009 guidance on PROs for product label
claims. RESULTS: Literature review results confirmed pruritus is a central feature
of AD and affects both daytime functioning and nighttime sleep in many AD pa-
tients. In addition, the effective treatment of pruritus represents an unmet need
among patients with AD. Nine PRO instruments measuring AD-related pruritus
were identified and evaluated. Only one of these measures had been developed
exclusively in patients with AD, and none of these measures were developed or
evaluated with the scientific rigor outlined in the FDA’s PRO guidance.
CONCLUSIONS: The results of this targeted review indicate the need for new treat-
ments that improve pruritus among patientswith AD. In addition, to communicate
this treatment benefit, the development of a newAD-related pruritus instrument is
warranted in order tomore accurately describe the effect of therapy on this impor-
tant disease symptom.
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A COMPREHENSIVE HEALTH IMPACT ASSESSMENT AND DETERMINANTS OF
QUALITY OF LIFE, HEALTH AND PSYCHOLOGICAL STATUS IN ACNE PATIENTS
Pagliarello C, di Pietro C, Tabolli S
IDI IRCCS, Rome, Italy
OBJECTIVES: . Measurement of acne impact on QoL, health and psychological sta-
tus. To analyse the relationship between socio-demographic variables, disease se-
verity and mental status on QoL of acne sufferers. METHODS: . Acne cases were
selected from a survey conducted in 2010. The Short-Form 12-Item Health Survey
and the Skindex-29 were used to assess health status and QoL. The 12-Items Gen-
eral HealthQuestionnairewas used to identify individuals at risk for non-psychotic
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psychiatric disorders (GHQ-positive). Physician (PhGA) and patient global assess-
ments were obtained. We investigated the variables involved in the QoL through a
logistic regression analysis. RESULTS: . 195 cases were analysed. 26% were GHQ-
positive, reporting an impact on health status due to acne worse respect other
chronic diseases. Males rather than females reported a poorer QoL. A GHQ-positive
status (Skindex-29 overall: OR 2.6;95% CI 1.20-5.60,p0.05, functioning:OR 2.5;95%
CI 1.17-5.44,p0.05, symptoms:OR 3.0; 95% CI 1.36-6.53,p0.01; emotions:OR 2.55;
95% CI 1.19-5.46,p0.05) and having a severe/very severe PhGA (Skindex-29 over-
all:OR 3.4; 95% CI 1.20-10.38,p0.05) were associated with a poor QoL. Age of onset
25 was linked to being GHQ-positive (OR 2.92; 95% CI 1.2-7.1, p0.05) controlling
for gender, marital status and educational level. CONCLUSIONS: . Acne is not a
minor disease in comparison with other chronic conditions. Age of patient is ca-
pable to influence GHQ status which in turn affects QoL.
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LIMITED ROLE OF MARITAL STATUS IN THE IMPACT OF DERMATOLOGICAL
DISEASES ON QUALITY OF LIFE
Tabolli S, Pagliarello C, di Pietro C, Abeni D
IDI IRCCS, Rome, Italy
OBJECTIVES:Health status, health services utilization, andmortality differ bymar-
ital status for both sexes in most conditions, but little is known about dermatolog-
ical diseases. To evaluatewhethermarital status is associatedwith the impact that
dermatological diseases have on quality of life (QoL). METHODS: Data from two
surveys on dermatological outpatients were pooled. Marital status, sex, age, and
educational level were analysed in relation to QoL (using the scales of the Skin-
dex-29 questionnaire: emotions, symptoms, and functioning) and psychological
well-being (using the GHQ-12 questionnaire). RESULTS:We obtained data on 5471
patients (59% females, 46% married). Married patients (both males and females)
had lower mean values on the emotions scale and higher mean values in the
symptoms scale of the Skindex-29 compared to singles. Statistically significant
differences were identified only inmen, for the emotions scale and for the GHQ-12.
Females had significantly higher mean scores than males on each of the Skin-
dex-29 scales and on the GHQ-12. A multiple logistic regression model including
age, gender, and marital status, showed significant results only for gender, with
women suffering a more severe impact than men on all scales. No effect was
observed for marital status. CONCLUSIONS: Married patients had a lower disease
impact on the emotions scale even if they suffered a higher impact on the symp-
toms scale. After multiple adjustments, however, gender seems to be more rele-
vant than marital status in the evaluation of the impact of skin conditions on QoL.
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PATIENT-REPORTED OUTCOMES IN A DENTAL PRACTICE-BASED RESEARCH
NETWORK:PEARL
Botello-Harbaum MT1, Collie D1, Matthews AG1, Vena DA1, Craig RG2, Curro FA2,
Thompson VP2
1The EMMES Corporation, Rockville, MD, USA, 2New York University College of Dentistry, New
York, NY, USA
OBJECTIVES: Patient-reported outcomes (PROs) such as quality of life, satisfaction
with treatment, and health status provide the patients’ viewpoint on how their
diagnosis impacts their daily lives. In dentistry, PRO use, value and logistics in the
dental practice setting remain an area for further consideration. This paper de-
scribes the PEARL PRO characteristics and discusses their implementation in a
dental PBRN setting. METHODS: The Practitioners Engaged in Applied Research
and Learning (PEARL) network has conducted 7 clinical studies in the practice-
based setting. These studies included PROs related to: oral health impact (OHIP
-14), tooth sensitivity, pain medication, and implant esthetics questionnaire. The
Food and Drug Administration issued a Regulatory Guidance on PROs which was
used as the framework for evaluation of the PRO measures. RESULTS: Of the 7
PEARL clinical studies, all used the OHIP-14, 5 studies measured tooth sensitivity
and pain medication, and one study measured patient satisfaction. A total of 6077
patients have completed the OHIP-14 scale, 2,976 patients have completed the
tooth sensitivity questionnaire, and the implant esthetics and sensitivity question-
naires have been completed by 332 patients. PROsmeasures differed in their num-
ber of items, mode of administration, and domains. We found consistent associa-
tion between the tooth sensitivity and the OHIP-14measures across PEARL studies.
CONCLUSIONS: The value of PROs in dentistry in the context of a dental practice-
based research network (PBRN) has received limited attention. Our study found
that collecting PROs is possible and that they represent an indicator of the effec-
tiveness of a dental treatment. More work is needed to inform dental practitioners
on the value of thesemeasures and to enhance themeasurement properties of the
questionnaires. The PEARL network has used several PRO measures with diverse
characteristics to adapt to the dental practice setting and to measure the dental
condition.
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ACTINIC KERATOSIS PATIENTS ARE WILLING TO PAY FOR SHORTER
TREATMENT AND LOCAL SKIN RESPONSE DURATION AND INGENOL
MEBUTATE GEL IS LIKELY TO INCREASE PATIENT LIKELIHOOD OF SUCCESSFUL
COMPLETION OF TOPICAL TREATMENT
Willis M1, Erntoft S2, Persson S1, Norlin J1, Persson U1
1The Swedish Institute for Health Economics, Lund, Sweden, 2LEO Pharma A/S, Ballerup,
Denmark
Ingenol mebutate gel is a new treatment of Actinic Keratosis (AK). The adverse
effects of current AK drug treatment involve long-lasting local skin responses
(LSRs) which may influence patient adherence negatively. OBJECTIVES: Assess
patient=s willingness-to-pay (WTP) for accessing ingenol mebutate gel instead of
imiquimod 5%, imiquimod 3.75% and diclofenac 3% in a US setting and assess
patient=s likelihood of completing a full treatment course. METHODS: A web-sur-
vey (contingent valuation design) was sent to 2000 adults, including only AK diag-
nosed subjects with self-reported AK lesions on face/scalp and/or trunk/extremi-
ties, asking them their maximum WTP to receive access to ingenol mebutate gel
instead of one of three alternative drugs. The profile was varied in three dimen-
sions; duration of treatment and treatment-related local skin responses and com-
parator price. Respondents were also asked to rank the likelihood to successfully
complete treatment course. Internal validity was checked (hypothetical drug pro-
file and income effect). RESULTS: A total of 116 subjects (105 useful) responded
(response rate 53% if AKprevalence assumed to 11%). A total of 33% stated that they
followed treatment instructions fairly well (75% of the time) or to some extent
(50%), despite experience of LSRs. Almost 90 % rated ingenol mebutate gel as the
treatment they were most likely to successfully complete; 50-63% were willing to
pay extra (mean $475-518/course) to access ingenol mebutate gel instead of the
three treatment alternatives. Subjects with experience of drug treatment stated an
incrementalWTP (mean $820/course) for accessing ingenolmebutate gel instead of
imiquimod 3.75%. Subjects currently treating the full scalp or forehead stated an
incremental WTP (mean $674 respectively $726/course) for accessing ingenol
mebutate gel instead of imiquimod 5% and diclofenac 3%. CONCLUSIONS: There is
a substantial dissatisfaction with current AK treatments and clear evidence that
patients are willing to pay for shorter treatment and LSR duration.
SENSORY SYSTEMS DISORDERS – Health Care Use & Policy Studies
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DETERMINING ACCURATE DOSING OF USTEKINUMAB FROM SPECIALTY
PHARMACY DATA
Schmeichel-Mueller C1, Gunnarsson C2, Martin S3
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH,
USA, 3Centocor Ortho Biotech Services, LLC, Horsham, PA, USA
OBJECTIVES: To determine dosing patterns of ustekinumab, a biologic treatment
formoderate to severe plaque psoriasis, by analyzing prescription fill data and days
supplied from Diplomat Specialty Pharmacy (DSP). Ustekinumab is delivered as a
subcutaneous injection at weeks 0, 4, and every 12 weeks thereafter in two weight
based doses: 45mg and 90mg. METHODS: A retrospective analysis was conducted
of pharmacy fill data for patients18 years receiving2 fills of ustekinumab from
DSP between October 2009 to September 2010. Based on prescribing information
(PI), the expected time between first and second dose is 28 days / a 7-days and
the expected time between subsequent doses is 84 days/ a 14-day window. For
patients receiving 1 vial or syringe per fill, dosing was assigned based upon which
strength was initially filled. For patients receiving multiple vials or syringes per fill
(e.g. 45 mg  2), dose was based on days between fills. RESULTS: A total of 711
patients met inclusion criteria; 529 (74.4%) received one vial or syringe in the first
fill. A total of 182 patients received 2 vials or syringes, 125 (68.7%) conformed to
the expected days recommended from the PI. 57 patients (8.0%) had intervals that
fell before or after the expected time. Of the 654 (529  125) patients for whom
dosing patterns could accurately be assessed, 67.1% were dosed with 45mg.
CONCLUSIONS: Over 90% of patients had prescription fill data and intervals that
allowed for dosing patterns to be determined; the majority were dosed with 45mg.
Some patients receivedmultiple 45mg vials or syringes in one shipment, therefore
their dosing may be incorrectly interpreted as higher than their actual dose. To
appropriately analyze the dosing patterns of ustekinumab, one must account for
the number of vials or syringes supplied per fill, the strength, and the days between
fills.
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RELATIONSHIP BETWEEN WEIGHT AND DOSE IN PSORIASIS PATIENTS
TREATED WITH USTEKINUMAB
Schmeichel-Mueller C1, Goren A2, DiBonaventura MD3, Martin S4
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Kantar Health, Princeton, NJ, USA, 3Kantar
Health, New York, NY, USA, 4Centocor Ortho Biotech Services, LLC, Horsham, PA, USA
OBJECTIVES: To evaluate the relationship between weight and dose for patients
initiating ustekinumab, a biologic treatment for moderate to severe plaque psori-
asis. The recommended dosing for ustekinumab is 45mg for patients 100kg or
90mg for patients 100kg delivered as a subcutaneous injection at weeks 0, 4, and
every 12 weeks thereafter. METHODS: Patients receiving ustekinumab through
Diplomat Specialty Pharmacy (DSP) were surveyed to provide their weight. Inclu-
sion criteria were: 18 years, diagnosis of psoriasis and 2 doses of ustekinumab.
DSP provided ustekinumab shipment quantities and dates. Shipped quantities and
schedule were jointly used to estimate ambiguous doses (e.g., if two 45mg doses
were in the index shipment, the index dosewas estimated to be 90mg if the second
shipment was within 3-5 weeks; the index dose was estimated to be 45mg if the
next shipment was 12-18 weeks). RESULTS: Of 257 patients surveyed, 65% (166)
weighed100kg and 35% (91) weighed100kg. Of those100kg, 83% (138) received
a single 45mg index dose; 11% (19) received a single 90mg dose. Of those 100kg,
16% (15) received a single 45mg and 59% (54) received a single 90mg dose. Thirty-
one patients received two or more 45mg doses in the index fill (9 100kg and 22
100kg). Based on timing of the second fill for those patients, the index dose was
estimated to be 45mg and 90mg for 18 and 10 patients, respectively. Three patients
receiving two 45mgdoseswere not evaluable based on second fill date. In summary
by weight, 86% (142/166) of patients weighing 100kg are estimated to have re-
ceived an index dose of 45mg and 76% (69/91) of patients100kg likely received an
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